Eli Lilly & Co. (LLY) Misses Q2 EPS by 5c, Revenue Beats, Offers FY Guidance

Eli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $1.87, $0.05 worse than the analyst estimate of $1.92. Revenue for the quarter came in at $6.74 billion versus the consensus estimate of $6.65 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2021 EPS of $7.80-$8.00, versus the consensus of $7.90. Eli Lilly & Co. sees FY2021 revenue of $26.8-27.4 billion, versus the consensus of $27.22 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy